Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
Athira Pharma, Inc. (ATHA) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 8-K Quarterly results
Docs: "Athira Pharma Reports Second Quarter 2023 Financial Results and Pipeline and Business Updates Completed end of Phase 2 meeting and continued engagement with U.S. Food and Drug Administration Appointed Andrew Gengos as Chief Financial Officer and Chief Business Officer Maintains strong balance sheet to support innovative clinical development pipeline in neurodegenerative diseases through key inflection points BOTHELL, Wash., August 10, 2023 — Athira Pharma, Inc. , a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today reported financial results for the quarter ended June 30, 2023, and provided pipeline and business updates. “During the second quarter, we advanced and strengthened our pipeline ..."
05/11/2023 8-K Quarterly results
Docs: "Athira Pharma Reports First Quarter 2023 Financial Results and Recent Pipeline and Business Updates Phase 2/3 LIFT-AD trial of fosgonimeton for mild-to-moderate Alzheimer’s disease to focus on 40 mg dose Open label extension trial to be extended, providing up to 36 months of long-term exposure data ATH-1105 significantly prolongs survival and improves motor function in a mouse model of ALS; Strongly supports development as a treatment for ALS Strong balance sheet to support innovative clinical development pipeline in neurodegenerative diseases through key inflection points"
03/23/2023 8-K Quarterly results
Docs: "Athira Pharma Reports Full Year 2022 Financial Results and Recent Pipeline and Business Updates On track to complete enrollment in Phase 2/3 LIFT-AD trial of fosgonimeton for mild-to-moderate Alzheimer’s disease in mid-2023 with topline data in early 2024 Continuing to advance development of ATH-1105 as a potential clinical candidate for amyotrophic lateral sclerosis Strong balance sheet to support innovative clinical development pipeline in neurodegenerative diseases through key inflection points"
01/06/2023 8-K Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Financial Statements and Exhibits ...
Docs: "ATHIRA PHARMA, INC."
11/18/2022 8-K Quarterly results
11/10/2022 8-K Quarterly results
10/17/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Athira Pharma Advances Phase 2/3 LIFT-AD Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients Following Independent, Unblinded Interim Analysis Results support potential clinically meaningful activity of fosgonimeton without background therapy and mitigate program risk Updated study well powered for primary endpoint with addition of fewer than 150 patients Company targets completion of enrollment in mid-2023 and topline results in early 2024 Company to host live webcast today at 8:30 a.m. Eastern BOTHELL, Wash., Oct. 17, 2022 — Athira Pharma, Inc. , a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that following an unblinded interim efficacy and futility analysis, ...",
"LEARNINGS FROM ACT-AD INFORM STUDY DESIGN OPTIMIZATION"
08/15/2022 8-K Quarterly results
06/22/2022 8-K Quarterly results
05/24/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
03/24/2022 8-K Quarterly results
Docs: "Athira Pharma Reports Full Year 2021 Financial Results and Provides Clinical Update On track to report topline data from ACT-AD Phase 2 Alzheimer’s disease study in 2Q22 Expect to complete enrollment in LIFT-AD Phase 3 Alzheimer’s disease study in 3Q22 Conference call today at 4:30 pm Eastern time BOTHELL, WA, March 24, 2022 — Athira Pharma, Inc. , a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the company’s financial results for the year ended December 31, 2021 and provided a clinical update. “We entered 2022 with strong momentum from the solid foundation established throughout 2021 and have made considerable progress across a number of areas key to our success,” sta..."
03/21/2022 8-K Appointed a new director
Docs: "Athira Pharma Announces Appointment of Dr. Michael A. Panzara to its Board of Directors"
01/31/2022 8-K Appointed a new director
Docs: "Amended and Restated Change in Control and Severance Agreement between the Company and Mark Litton, Ph.D",
"Outside Director Compensation Policy, as amended",
"Athira Pharma Announces Appointment of Grant Pickering to its Board of Directors"
11/10/2021 8-K Quarterly results
Docs: "Athira Pharma Reports Third Quarter 2021 Financial Results and Business Update – Completed enrollment of ACT-AD trial with topline data expected in the first half of 2022; LIFT-AD is actively recruiting with topline data expected by the end of 2022 – – Presented program updates and baseline data from ATH-1017’s ongoing Phase 2 and Phase 2/3 clinical trials at the 2021 CTAD conference – BOTHELL, Wash., November 10, 2021 — Athira Pharma, Inc. , a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today reported its financial results for the third quarter ended September 30, 2021, and provided an update on the company’s operations. “We remained focused on our development efforts during the third qua..."
10/21/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Separation Agreement between Leen Kawas and Athira",
"Athira Pharma Announces Leadership Changes; Mark Litton, Ph.D., M.B.A. Named President and Chief Executive Officer; Rachel Lenington, M.B.A. Named Chief Operating Officer"
08/16/2021 8-K Quarterly results
08/09/2021 8-K Quarterly results
06/17/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Athira Pharma Chief Operating Officer, Mark Litton, Assumes Day-to-Day Leadership Responsibilities of Company"
06/01/2021 8-K Quarterly results
05/13/2021 8-K Quarterly results
03/25/2021 8-K Quarterly results
03/08/2021 8-K Quarterly results
01/11/2021 8-K Quarterly results
12/14/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Athira Pharma Announces Appointment of Kelly A. Romano to its Board of Directors"
11/12/2020 8-K Quarterly results
Docs: "Athira Pharma Reports Third Quarter 2020 Financial Results and Provides Business Highlights - LIFT-AD clinical trial evaluating ATH-1017, a once-daily investigational drug for the treatment of mild-to-moderate Alzheimer’s disease, actively enrolling"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy